Global Metastatic Bone Disease Market Size, Share, Growth Trends, and Forecast 2032

What is the Market Size of Metastatic Bone Disease Industry?

The global Metastatic Bone Disease market size accrued earnings worth approximately USD 17.24 Billion in 2023 and is predicted to gain revenue of about USD 35.93 Billion by 2032, is set to record a CAGR of nearly 8.5% over the period from 2024 to 2032.

Request Free Sample

Key Insights

• As per the analysis shared by our research analyst, the metastatic bone disease market is anticipated to grow at a CAGR of 8.5% during the forecast period (2024-2032).
• The global metastatic bone disease market was estimated to be worth approximately USD 17.24 billion in 2023 and is projected to reach a value of USD 35.93 billion by 2032.
• The growth of the metastatic bone disease market is being driven by growing as the global incidence of cancer rises and survival rates improve, leading to a larger population of patients who develop bone metastases from primary tumors such as breast, prostate, and lung cancers.
• Based on the treatment, the medication segment is growing at a high rate and is projected to dominate the market.
• On the basis of origin, the breast segment is projected to swipe the largest market share.
• In terms of end-user, the hospitals segment is expected to dominate the market.
• By region, North America is expected to dominate the global market during the forecast period.

Metastatic Bone Disease Market Development and Outlook

As there are various developments being made in the research field there is also a constant increase in the number of various diseases such as cancer, autoimmune diseases, and others. Bone metastasis is an advanced stage of cancer which spread to other parts of the body which mainly includes lung, liver, and bones. This will add up the treatment cost and the chances of getting cured also reduce. Bone metastasis leads to the degeneration of bones and can cause various fractures which cannot be treated. This can cause severe pain, anemia, spinal cord compression, hypercalcemia, and various other conditions. This can be diagnosed by CT scan and treatment includes prevention and treatment of fractures, pain control, local tumor control, and maintenance of patient function. Treatment options are chosen on various factors which include performance status, impact on quality of life, life expectancy, and the overall status of the clinical disease.

There is a constant increase in the prevalence of cancer over the period of time and reimbursement policies are the major factors driving the growth of metastatic bone disease market over the forecast period. Cancer begins in an organ and then spreads to bones and as per the National Cancer Institute in 2018 an estimated 1,735,350 new cases of cancer will be diagnosed in the United States. The companies are also focused towards developing new and effective treatments for the cancer patients which will further help in providing a better life.

The companies are constantly investing in research and development and there are various new drugs being developed by the companies and few are under development. This may further fuel the metastatic bone disease market over the forecast period. Moreover, there are various drugs approved by FDA for treatment and various organizations are creating awareness among people will also support the growth of metastatic bone disease market. However, the high cost of research and development and long duration of product development may hamper the growth of the metastatic bone disease.

In order to give the users of this report a comprehensive view of the metastatic bone disease market, we have included competitive landscape and analysis of Porter’s Five Forces model in the market. The study encompasses a market attractiveness analysis, wherein treatment, origin, end use, and regional segmentation are benchmarked based on their market size, growth rate, and general attractiveness.

The report provides company market share analysis in order to give a broader overview of the key players in the market. In addition, the report also covers key strategic developments in the market, including acquisitions & mergers, new treatment launch, agreements, partnerships, collaborations & joint ventures, research & development, regional expansion of major participants involved on the market on the global and regional basis.

Request Free Sample

Metastatic Bone Disease Market: Report Scope

Metastatic Bone Disease Market Segmentation Analysis

The study provides a decisive view on the metastatic bone disease market by segmenting the market based on test type, drug type, distribution channel, and regions. All the segments have been analyzed based on present and future trends and the market are estimated from 2024 to 2032. 

Based on treatment, the metastatic bone disease market is segmented as medication, radiation therapy, surgical intervention, and tumor ablation therapy. Based on origin, the metastatic bone disease market is segmented as breast, lung, thyroid, kidney, prostate, and others. Based on the end user, the metastatic bone disease market is segmented as hospitals, specialty clinics, and ambulatory surgical centers

Increased prevalence of cancer is one of the major driving factors of metastatic bone disease market. High investment on the drug discovery and development which is further supported the FDA approval of various drugs for the treatment of metastatic bone disease market. A long interval of time is required for the developments of drugs are the factors that influence the market growth during the forecast period.

Recent Development

• In March 2025, the FDA approved Stoboclo and Osenvelt (CT‑P41, denosumab‑bmwo), biosimilars referencing denosumab, for all indications covered by the reference product—including the prevention of skeletal-related events in patients with bone metastases and other cancer-associated bone damage.
• In December 2021, Zetagen Therapeutics received Breakthrough Device designation from the FDA’s Center for Devices and Radiological Health for its ZetaMet technology, a novel therapeutic approach targeting metastatic bone lesions and related conditions.
• In September 2025, Biocon Biologics secured FDA approval for its denosumab biosimilars Bosaya and Aukelso. Notably, Aukelso is indicated for preventing skeletal-related events in patients with multiple myeloma and those with bone metastases from solid tumors.
• In March 2025, Novartis entered a strategic partnership with Progenics Pharmaceuticals to co-develop and commercialize PSMA-targeted radiopharmaceutical therapies for cancers characterized by bone-dominant metastases, aiming to broaden treatment options in this domain.
• In 2025, Roche formed a collaboration with Ipca Laboratories to advance the development and distribution of radiopharmaceuticals and companion diagnostics focused on bone metastases, with a particular emphasis on expanding access across emerging markets.

Metastatic Bone Disease Market Regional Analysis

In terms of region, the global metastatic bone disease market is classified into North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America. North America is expected to be the largest market for metastatic bone disease market which is further followed by Europe during the forecast period. This growth is supported by an increase in healthcare facilities and an increase in research and development which is further supported by FDA approval of the various new drugs launched in the market. The Asia Pacific is expected to experience a significant growth due to the increased prevalence and awareness among people. Latin America and the Middle East and Africa are expected to experience a moderate growth over the forecast period.

Metastatic Bone Disease Market: Competitive Analysis

The report also includes detailed profiles of end players such as

• Merck & Co., Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Amgen, Inc.
• Novartis AG
• Bayer AG
• BTG plc
• Fresenius Kabi AG
• Medtronic
• Boston Scientific Corporation, and others. 

This report segments the global Metastatic Bone Disease Market as follows:

By Treatment

• Medication
• Radiation Therapy
• Surgical Intervention
• Tumor Ablation Therapy

By Origin

• Breast
• Lung
• Thyroid
• Kidney
• Prostate 
• Others

By End-User

• Hospitals
• Specialty Clinics
• Ambulatory Surgical Centers

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America